Las Vegas, NV -- (SBWIRE) -- 09/23/2013 -- PennyStockEarnings team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks. Our Today’s Focus is on: The New York Times Company (NYSE:NYT), Raptor Pharmaceutical Corp. (NASDAQ:RPTP), Gol Linhas Aereas Inteligentes SA (ADR) (NYSE:GOL), Orexigen Therapeutics, Inc. (NASDAQ:OREX)
The New York Times Company (NYSE:NYT) managed to keep its gain at 1.04% on above-normal volume of 2.30M shares. The stock settled at $11.66 after floating in a range of $11.54 to $11.75. Its latest price has reached market capitalization of $1.74 billion. Its 52-week range has been $7.72 to $12.84.
The New York Times Company operates as a multimedia news and information company worldwide. The company operates in two segments, The New York Times Media Group and the New England Media Group.
For How Long NYT will fight for Profitability? Read This Trend Analysis report
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) traded down on a volume of 3.22 million, higher than its standard daily volume. Shares have dropped-0.97% to $14.36. Over the last twelve months, the stock has gained 163% and faced a worst price of $4.35.
Raptor Pharmaceuticals Corp. (RPC), formerly TorreyPines Therapeutics, Inc., is an early development-stage Company. The Company’s product portfolio includes both candidates from its drug targeting platforms and in-licensed and acquired product candidates. As of August 31, 2010, its pipeline includes three clinical development programs.
Has RPTP Found The Bottom And Ready To Gain Momentum? Find Out Here
Gol Linhas Aereas Inteligentes SA (ADR) (NYSE:GOL) settled -4.76% lower at $4.80 on below -normal volume of 2.25M shares during the last trading day. The stock has its 12-month high at $7.67 and 52-week low price was $2.74. It traded in a range of $4.78 to $5.04 during the last trading day.
Gol Linhas Aéreas Inteligentes S.A., through its subsidiaries, engages in the air transportation of passengers, cargo, and mailbags in Latin America.
Will GOL Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, Orexigen Therapeutics, Inc. (NASDAQ:OREX) was down on high volume, trading at a volume of 2.87M shares versus its average daily volume of 920,604.00 shares. At $6.55, the stock has attained market capitalization of $647.78 million.
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include Contrave, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic, which has completed Phase II clinical trials.
Why Should Investors Buy OREX After the Recent Fall? Just Go Here and Find Out
PennyStockEarnings.com is keen to discover penny stocks with the potential to make short and long-term gains.
PSE Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks.
PLEASE NOTE WELL: The employees of PennyStockEarnings.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockEarnings.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockEarnings.com is not offering securities for sale. Neither PennyStockEarnings.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockEarnings.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockEarnings.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer Here: http://www.pennystockearnings.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)